Hyatt Hotels Corporation vs Medpace Holdings Inc — how do they compare? Hyatt Hotels Corporation trades at $176.03 (market cap $16.27B), while Medpace Holdings Inc trades at $598.57 (market cap $16.90B). The key difference: Hyatt Hotels Corporation and Medpace Holdings Inc are close in size by market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| H | MEDP | |
|---|---|---|
Market Cap | $16.27B | $16.90B |
Sector | Consumer Cyclical | Technology |
52-Week High | $202.09 | $620.59 |
52-Week Low | $135.42 | $393.42 |
Enterprise Value | $20.17B | $16.52B |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corp (H) trades at $170.08, down 4.29% on the day, reflecting a bearish technical trend with key support at $167. Fundamentally, the company shows revenue growth to $7.10B in 2025 but reported a net loss of $52M, with a high P/E ratio of 213.14 indicating premium valuation. Recent Q2 2026 earnings beat expectations with EPS of $1.12, driven by strong fee growth and RevPAR gains, as reported by Business Wire on July 30, 2026.
The outlook is mixed; analyst consensus is a 'Hold' with a $199.55 price target, suggesting 17% upside, but high debt and regional weaknesses pose risks. Investment opportunity hinges on sustained operational momentum offsetting valuation concerns, with key risks including project delays and macroeconomic pressures on travel demand.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →